IPO Profile

Stereotaxis
4041 Forest Park Avenue, St. Louis, Missouri 63108
Tel: 314-615-6940
Web: www.stereotaxis.com
Ticker: STXS
Stock Exchange: Nasdaq
Shares Issued: 5,000,000.00
Price Offered: $8.00
Amount Raised: $40,000,000.00

Underwriters:
Goldman Sachs & Co.
Bear Stearns & Co.
Deutsche Bank Securities
A.G. Edwards & Sons


Company Description:
We design, manufacture and market an advanced cardiology instrument control system for use in the cath lab that we believe revolutionizes the treatment of coronary artery disease and arrhythmias by enabling important new therapeutic solutions and enhancing the efficiency and efficacy of existing interventional procedures. Our Stereotaxis System is designed to allow physicians to more effectively navigate proprietary catheters, guidewires and stent delivery devices, both our own and those we are co-developing with strategic partners, through the blood vessels and chambers of the heart to treatment sites and then to effect treatment. This is achieved using computer-controlled, externally applied magnetic fields that precisely and directly govern the motion of the working tip of the catheter, guidewire or stent delivery device. To our knowledge, we have no direct competitors in this field. We believe that our technology represents an important advance in the ongoing trend toward digital instrumentation in the cath lab and provides substantial, clinically important improvements and cost efficiencies over existing manual interventional methods. As a result, we believe that the Stereotaxis System has the potential to become the standard of care for a broad range of complex cardiology procedures.